---
title: "Esophageal Cancer Treatment"
format: 
  revealjs:
    slide-number: c/t
    width: 1600
    height: 900
    logo: "atriumlogo.jpg"
    footer: "[GI Surgical Oncology Talks](https://gisurgonc.github.io/talks/)"
    css: "lci_styles.css"
    theme: [simple, lci.scss]
    echo: false
  #nanotes_pdf: default
  pdf:
    includes:
      in-header: "preamble.tex"
  #pptx: 
    #reference-doc: talks.pptx
editor: visual
bibliography: zotero.bib
---

## Lymphadenectomy

Retrospective data from Japan in the 1980's suggested superior survival after extended lymphadenectomy for gastric cancer.

Extent of lympadenectomy can be categorized:

D1: Perigastric D2: Central nodes + splenic hilum D2$\alpha$: Central nodes D3: Extended nodes

## D1 Perigastric nodes

Lymph node stations immediately adjacent to the stomach

-   1:
-   2:
-   3: Lesser curvature
-   4: Greater curvature
-   5: Suprapyloric
-   6: Infrapyloric

## D1 Perigastric Nodes

![](https://deidt7p41jzcy.cloudfront.net/songun-gr1_lrg_D1_1980.png)

## D2 Central Nodes + splenic hilum

Lymph nodes adjacent to celiac axis:

-   12a: Left side of porta hepatis
-   8: Common hepatic artery
-   7: Left gastric artery
-   9: Celiac axis
-   11: Proximal splenic artery
-   10: Splenic hilum

## D1$\alpha$ Central Nodes

Lymph nodes adjacent to celiac axis:

-   12a: Left side of porta hepatis
-   8: Common hepatic artery
-   7: Left gastric artery
-   9: Celiac axis
-   11: Proximal splenic artery
-   ~~10: Splenic hilum~~

## D2 Central Nodes

![](https://deidt7p41jzcy.cloudfront.net/songun-gr1_lrg_D2_1980.png)

## Durch Trial: D2 vs D1 Lymphadenectomy


## MRC Trial: D2 vs D1 Lymphadenectomy

Operative mortality higher with D2 (10% vs 4%)

More complicatoins wtih D2 (43% vs 25%)

More reoperations with D2 (18% vs 8%)





737 patients with gastric cancer registered

Staging laparotomy found 337 patients ineligible

- Liver or peritoneal metastasis
- Para-aortic node involvement on frozen

400 patients randomized to D1 vs D2 lymphadenectomy

Distal gastrectomy allowed if proximal margin of 5cm

Total gastrectomy in all others


## MRC Trial: D2 vs D1 Lymphadenectomy

737 patients with gastric cancer registered

Staging laparotomy found 337 patients ineligible

- Liver or peritoneal metastasis
- Para-aortic node involvement on frozen

400 patients randomized to D1 vs D2 lymphadenectomy

20409751

## Esophageal Cancer Treatment Categories

| Category             |   Stage    | Treatment                  |
|----------------------|:----------:|:---------------------------|
| [Dyplasia]           |    Tis     | Radiofrequency Ablation    |
| [Superficial Tumors] |    T1a     | Endoscopic Therapy         |
| [Localized Tumors]   |   T1b T2   | Surgery                    |
| \[Locally-advanced\] | T3 or N^+^ | ChemoRT â†’ Surgery          |
| \[Metastatic\]       |     M1     | Chemotherapy +/- Radiation |

## Dyplasia

Radiofrequency Ablation for Dysplasia

::::: columns
::: {.column width="60%"}
127 patients with dysplasia randomized:

-   Radio-frequency ablation
-   Sham ablation

Low-grade dysplasia in 64

High-grade dysplasia in 63
:::

::: {.column width="40%"}
![](images/rfa_esophagus.png) ![Barxx](images/barxx.png)
:::
:::::

::: aside
[@shaheen2277]
:::

## Radiofrequency Ablation for Dysplasia

::::: columns
::: {.column width="30%"}
Radiofrequency Ablation results in eradication of Barrett's in 75% at 1 year
:::

::: {.column width="70%"}
![](images/shaheen.png)
:::
:::::

::: aside
[@shaheen2277]
:::

## Superficial Tumors

Workup of nodular Barretts:

-   Endoscopic Ultrasound
-   Endoscopic Mucosal Resection
    -   Diagnostic (T staging)
    -   May be therapeutic for T1a tumors

## Endoscopic Musocal Resection

![](images/EMR.jpg){fig-align="right"}

## Localized Tumors

Patients staged as uT2 N0 are candidates for primary surgery. *However:*

-   EUS has a 25% rate of understaging uT2 N0 tumors
-   Understaged patients who undergo primary surgery would need chemo or chemoRT postop

## Small Tumors (minimal dysphagia)

-   EUS to distinguish T2 from T3 tumors
-   If uT2 N0 $\rightarrow$ CT chest/abdomen/pelvis $\rightarrow$ Esophagectomy
-   If uT3 or N1 $\rightarrow$ PET $\rightarrow$ neoadjuvant therapy

Patients with dysphagia almost always are T3 tumors (and don't need EUS)

## Symptomatic Tumors (Dysphagia)

Patients with dysphagia to solids or weight loss or tumor length \>3cm are unlikely to have T1-2 tumors and can be initially evaluated with \[PET Scan\]

-   Disease confined to the esophagus and regional nodes $\rightarrow$ \[Locally-advanced\]
-   Metastatic disease $\rightarrow$ \[Metastatic\]
-   N3 $\rightarrow$ induction chemotherapy followed by chemoradiation and surgical evaluation.
